Company intelligence / Profile preview

Antisense Pharma

Regensburg, Bavaria, Germanyionis.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Antisense Pharma GmbH develops innovative antisense oligonucleotide therapies targeting the TGF-beta pathway to treat aggressive cancers. Its lead program advanced to Phase III trials for high-grade glioma. The company’s pipeline includes candidates for several solid tumors, leveraging proprietary antisense technology to block synthesis of key cancer proteins. The company has received innovation awards in Germany and continues R&D on next-generation compounds.

Therapeutic areas: Oncology
Modalities: Antisense oligonucleotides
Industry: Biotech

Drug pipeline

1 asset

AP 12009

Phase 2

Indications: Brain tumor

Partnerships

No major pharma partnerships specifically named in public sources.

Beyond the preview

Go deeper on Antisense Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antisense Pharma.